SALT LAKE CITY, UT / ACCESSWIRE / August 27, 2015 / With continued legislation placing restrictions and regulations on the production of coal, along with production costs of natural gas declining thanks to new technologies, natural gas has emerged as a premier energy source. This week’s $12 billion acquisition of AGL Resources by Southern Company was a prime example of the move toward natural gas by major energy companies. The deal makes Southern Company the second biggest utility company in the U.S. as determined by number of customers.

But a deal like this only happens after maturation of a company into a market leader, and sophisticated investors identify possibly the next up-and-coming company that could one day be involved in such a deal. One possibility may be Arkose Energy (RKOS). The company has recently placed a greater emphasis on natural gas, and seeks to grow in leaps and bounds by adopting a philosophy that places an emphasis on minimizing expenditures to maximize production and gains. One example of this philosophy in practice finds Arkose mainly treating contaminated well water on site, rather than allocating valuable resources to trucking and disposal costs. With these types of green energy practices in place and on the rise, the company could soon begin to appeal to investors interested in environmental and green markets, opening itself to a more diversified investor base.

But no up-and-comer can get by on a strong philosophy alone, and Arkose has answered the call with several recent moves that could lead to steady growth over the months to come. Earlier in the year, the company acquired an oil and gas lease in Eastland County, Texas, an area where the company believes there could be deeper zones to drill and develop than previously thought. This falls right into the company’s philosophy: use ingenuity and resources to identify an asset that can be acquired at minimal cost, then take advantage of that asset’s upside value to maximize its potential for yielding possible company gains.

Another player in oil and gas resources Warren Resources Inc. (WRES). Trading .35 per share, this company has also been creating some headlines in recent weeks. In addition to presenting at the Entercom Oil and Gas conference in Denver, Warren Resources also released results from initial completons on two Upper Marcellus wells: 17 Mmcf per day with 3% of flowback load recovered. CEO Lance Peterson said he was encouraged by these initial results and that the company “expects to see these wells continue to clean up and experience increased flow rates.”

Like Arkose, SolarWindow Technologies Inc. (WNDW) is another company to delve into some clean energy practices. The company produces a tinted coating that can be applied to see-through glass, which generates electricity from both natural and artificial light sources. Last week, the company released an exciting new video of one of its products in action.

Black Stallion Oil and Gas (BLKG) could be another stock to watch in the coming weeks. Trading at 1.55 per share, the company made headlines this week by appointing industry veteran Michael L Pinnell as the company’s VP of Exploration. Pinnell’s experience in the field dates back 45 years to when he began his career with Exxon. Additionally, the company’s focus on Alberta Basin Bakken in Montana could yield new results in the coming months, as this area shares characteristics with nearby established basins yielding huge amounts of natural gas.

These companies exemplify U.S. trends toward uncovering new energy sources, as well new practices used for production of established energy sources like oil. Natural gas has emerged as one of the more promising markets in the financial sector, and given recent events, up-and-coming natural gas stocks like RKOS might be one for the radar screens of investors looking into natural gas companies.

DISCLAIMER:

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

SOURCE: Seraphim Strategies

ReleaseID: 431585

NEW YORK, NY / ACCESSWIRE / August 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on SITO Mobile Ltd. (NASDAQ: SITO) highlighting NASDAQ Uplisting and other recent developments.

The report is available here: SITO Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

SITO Mobile Ltd. (NASDAQ: SITO, “SITO Mobile”) is a leading mobile engagement platform provider based in Jersey City, NJ, whose messaging and location-based advertising platforms are used by major consumer brands and retailers in the US to interact with their customers via mobile communications. SITO Mobile has made impressive progress since we initiated coverage on the company in February 2015 – demonstrating impressive growth, improving its capital structure, completing a strategic acquisition, and recently achieving an uplisting to the NASDAQ Capital Markets. We see continued catalysts ahead for the company due to the growing traction of its location-based platform and synergies from HipCricket transaction, which we believe is operating at a annual revenue run rate of $5-$6mn in addition to adding complementary technology and highly attractive customers.

Highlights from the Update Note are as follows:

NASDAQ listing caps a year of significant progress for SITO

On August 10, SITO shares officially began trading on the NASDAQ Capital Market. The NASDAQ listing capped a year of significant work for he company, which included strong revenue growth, improvements to its capital structure, acquiring HipCricket’s mobile advertising business, and executing a 1:10 reverse stock split in July. In our view the NASDAQ listing is a major milestone for SITO, as the move should raise the company’s profile in its industry, with advertising clients, and with investors. We expect the NASDAQ listing to improve SITO’s trading liquidity and enable access to a broader group of potential institutional investors.

Top line continues to rise rapidly in 3Q15

SITO reported powerful annual revenue growth in its fiscal 3Q15, with the company’s top line rising nearly 72% from year-ago levels to reach $3.7mn. Media Placement sales represented 59% of revenues and grew over 30% sequentially, led by increased traction in the company’s real-time mobile location-based advertising platform. We continue to see SITO as an intriguing emerging player in the fast-growing $30Bn programmatic mobile advertising market. SITO also reported gross margins ahead of our expectations, with 3Q15 gross margins of 60.7%, above our long-term expected range of the mid-to-high 50%.

Acquisition positions SITO as a leader in mobile engagement

On July 9, 2015, SITO completed the acquisition of the mobile advertising business of distressed rival HipCricket for $3.7m in a cash and stock transaction, marking the completion of a year long process. The acquisition appears to be well matched for SITO, as Hipcricket specializes in mobile engagement solutions and marketing analytics, complementary areas to the SITO core business. In addition to complementary technology, the HipCricket mobile advertising business should significantly expand SITO’s customer base. The company’s disclosed that they only had a 5% overlap in customers, and the HipCricket mobile ad business counts some of the nation’s the largest telecom carriers among its customers – key strategic additions for SITO. Our research suggests that the acquired HipCricket business should be operating at an annual run rate of between $5-$6mn, with gross profit margins in the mid-50% range.

Price target moves to $7.40 in light of share consolidation

We are adjusting our SITO price target to reflect the company’s recent 1:10 share consolidation. Previously, our target for SITO was $0.74. We have been impressed by the myriad accomplishments from SITO management since we initiated coverage on the company in February. If achieved, the price target of $7.40 suggest potential upside of 90.7% form the recent price of $3.88.

Please review important disclosures on our website at www.seethruequity.com.

About SITO Mobile Ltd.

SITO Mobile provides a mobile engagement platform that enables brands to increase awareness, loyalty, and ultimately sales. For more information visit www.sitomobile.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 431568

NEW YORK, NY / ACCESSWIRE / August 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Opexa Therapeutics, Inc. (NASDAQ: OPXA) with a Price Target of $3.06.

The report is available here: OPXA Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Headquartered in The Woodlands, TX, Opexa is an innovative biopharmaceutical company focused on developing precision immunotherapy initially targeting secondary progressive multiple sclerosis (SPMS) and neuromyelitis optica (NMO). The company’s lead drug candidate, Tcelna (R), is being developed as a potential therapy of choice in SPMS, a $7Bn+ annual market with limited competition. Tcelna (R) received fast track designation from the FDA and has attracted support from a strong potential partner in Merck-Serono. Beyond Tcelna (R), Opexa is also developing OPX-212, a preclinical compound intended for neuromyelitis optica (NMO), an orphan indication with no approved therapies. Longer term, we believe the company is focused on leveraging its proprietary technology and broad intellectual property (IP) portfolio to develop a personalized T-cell immunotherapy platform that can be leveraged for treatment of a number of autoimmune diseases, with the potential to yield multiple candidates tailored to each patient’s disease profile. 

“We see the next twelve months as potentially game-changing for Opexa, as the company is nearing completion of a high profile Phase 2b clinical trial for its lead personalized immunotherapy candidate, Tcelna (R) for SPMS. We have high hopes for Tcelna (R) in what Opexa has dubbed the Abili-T Phase 2b clinical trial, which is designed to determine whether Tcelna (R) could improve clinical outcomes of SPMS patients. Opexa has designed Tcelna (R) to be a first line treatment for the $7Bn+ annual market for SPMS by taking a differentiated, personalized approach to treating MS, with the treatment specifically tailored to each patient’s immune response profile to myelin. Tcelna (R) received fast track designation from the FDA for SPMS, and demonstrated encouraging results in earlier Phase I/II trials – with 80% of patients showing no disease progression after two years of treatment. The candidate has also attracted the interest of major pharmaceutical companies, signing an option and license agreement with Merck-Serono in 2013 that could be worth up to $220mn in future license and milestone fees, in addition to royalties,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $3.06 per share.”

Additional highlights from the report are as follows:

Abili-T Phase 2b trial top line results on the horizon

We have high hopes for Tcelna (R) in Opexa’s “Abili-T” Phase 2b clinical trial, which is designed to determine whether Tcelna (R) could improve clinical outcomes of SPMS patients. According to management, patient visits in the two-year, double blind, placebo controlled, Abili-T study were over 85% complete, with completion and top line results expected in the second half of 2016E. Opexa completed a rights offering in April with net proceeds of $12mn, giving the company a clear runway to complete the trial. 

Large market opportunity attracting Big Pharma interest

MS is a chronic, inflammatory condition of the central nervous system that affects approximately 2.5mn people globally and 450,000 people in North America, according to the National MS Society. Tcelna (R) received a fast track designation from the FDA for potential treatment of SPMS, and demonstrated encouraging results in earlier Phase I/II trials – with 80% of patients showing no disease progression after two years of treatment. Opexa aims for Tcelna (R) to be a first-to-market, personalized T-cell therapy for MS patients, which assuming 150,000 patients with SPMS in North America, could represent a potential market greater than $7Bn per year. If approved, Opexa looks to face limited competition in this large market from FDA-approved SPMS treatments, presenting an opportunity for Tcelna (R) to emerge as a blockbuster drug assuming its efficacy is supported by Phase 2b results.

Potential licensing deal with Merck-Serono enhances opportunity

Tcelna (R) has also attracted the interest of major pharmaceutical companies, with Opexa signing a global option and license agreement with Merck-Serono in 2013 that could be worth up to $220mn in future license and milestone fees and an attractive potential royalty rate of 8% – 15% depending on sales levels. If it exercises the option to license Tcelna (R), Merck-Serono would also fund Phase 3 clinical trials and commercialization costs. Merck-Serono has until the release of the Abili-T results to exercise the option to license Tcelna (R), adding to the importance of strong efficacy data from the Phase 2b trial. Clearly a potential partnership with Merck-Serono would be a significant catalyst and potentially transformative development for Opexa.

Please review important disclosures on our website at www.seethruequity.com. 

About Opexa Therapeutics, Inc.

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna (R), is a personalized T-cell immunotherapy that is in a Phase 2b clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient’s peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 431575

LOS ANGELES, CA / ACCESSWIRE / August 27, 2015 / Medbox, Inc. (OTCQB: MDBX), a provider of specialized services to the cannabis sector, including operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved, today announced it has entered the state of Washington, with an agreement to consult on the opening of a new marijuana dispensary.

Under the agreement, Medbox will provide specialized consulting services to the principals and operators of the Fweedom Collective medical dispensary in Seattle for the opening of a new 502 recreational retail dispensary in Mt. Vernon, WA. The new dispensary is scheduled to be operational in the first half of 2016.

In addition to having procured the new location, Medbox will provide the owners with both pre- and post-opening services, including advising on regulatory compliance, security, training, IT and associated matters. The dispensary, which is expected to sell the new personal vaporizer – miVape – which is produced by Medbox’s Vaporfection subsidiary, will be under the exclusive supervision and control of the Fweedom owners.

“The agreement with the principals of Fweedom is significant to Medbox since it represents our initial entry into the Washington market, where marijuana has been approved both for medical and recreational use, and where we believe potentially outstanding business opportunities exist,” said Jeff Goh, President and interim Chief Executive Officer of Medbox. “It also supports our business objective of securing a recurring revenue stream, along with our mission of helping to ensure that patients have access to quality products in the areas in which they live.”

“We look forward to a long and productive association with the principals of Fweedom, who have established a professional organization, adhering to the highest industry standards. We believe Fweedom is destined to become one of the state’s largest dispensary operations,” Goh added.

“We selected Medbox for its depth of expertise on a national scale, as one of the nation’s premiere service providers in our sector,” said J. Tyler Godfrey one of the principals of Fweedom. “While we believe our industry and our company are on a fast-growth trajectory, there are many complex issues from start-up and operational perspectives. With Medbox as our partner, we are confident of having the right formula for success.”

About Fweedom Collective

Founded in 2008 in Seattle, Fweedom, which currently operates a medical marijuana dispensary, started as a hemp alternative-based clothing company, bringing awareness to consumers of hemp and fabrics opposed to traditional cotton. The company evolved into a medical marijuana collective in 2011.

About Medbox, Inc.

Medbox, Inc., a leader in the rapidly emerging cannabis sector, provides specialized services to operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved. Through trusted clients and affiliates, the company promotes efficient, consistent, high quality products that are priced right, readily available and safely packaged. For more information about the company or to explore partnership, please visit www.medbox.com.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements, including, but not limited to, the timing of the opening of the new dispensary and business opportunities in the state of Washington, are based on current beliefs and expectations and are inherently subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the company’s control. In addition, certain forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties also include, but are not limited to, regulatory developments in the industry, as well as political and economic conditions present within the industry. For a more detailed description of the risk factors associated with the company, please refer to the company’s latest Annual Report on Form 10-K, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter.The company does not assume any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made, unless required by law.

For more information, contact:

Janet Simmons
PondelWilkinson Inc.
310-279-5980
pwinvestor@pondel.com

SOURCE: Medbox, Inc.

ReleaseID: 431565

GPS SmartSoles Recognized for Innovation in Wearables, Health, Fitness & Wellness

LOS ANGELES, CA / ACCESSWIRE / August 27, 2015 / GTX Corp (OTCQB: GTXO), an IoT platform and leading provider of personal location GPS wearable technology and wandering assistive technology, announced today its flagship GPS SmartSoles were named a top 5 finalist in the Wearables, Health, Fitness & Wellness category at CTIA’s Hot for the Holidays Awards competition. Timed for the holiday buying season, the Hot for the Holidays Awards recognize the hottest mobile consumer electronics, devices, wearables, accessories and entertainment, home and car products. Winners will be announced Thursday, September 10 at CTIA Super Mobility 2015 at the Sands Expo in Las Vegas.

The GPS SmartSole(R) is a non-visible GPS tracking device designed to monitor the location of people afflicted with cognitive memory disorders, such as Alzheimer’s, dementia, autism and TBI, who have a tendency to wander and for people at risk of kidnapping, such as government employees and high level executives. In a recent Q2 Report, GTX Corp mentioned the next Gen SmartSole will be smaller, have more features such as a motion sensor, a longer battery life, 2G, 3G and LTE compatible and an expected 20% reduction in cost.

“Being a finalist in the 2015 CTIA Hot for the Holidays Awards and being recognized by a panel of industry experts, which judge hundreds of submissions is quite an honor, commented Patrick Bertagna, GTX Corp Chief Executive. And to be identified and selected as being among one of the best in the industry with tech giants such as – Google, Microsoft, Samsung and AT&T, is extremely rewarding and a true testament to the passion and commitment of the GTX product development team.”

“CTIA awards recognize some of the best mobile products and services that leverage shape and transform our competitive and rapidly evolving mobile industry. These awards are perfectly timed for holiday buying and new year business planning, and CTIA Super Mobility 2015 attendees will have the opportunity to see and experience these innovations first hand,” said CTIA Vice President and Show Director Robert Mesirow.

Dozens of industry experts, reporters and analysts judged and scored hundreds of entries to determine the finalists and winners in CTIA’s annual awards program. CTIA will host the awards ceremony at CTIA Super Mobility 2015 and announce the winners Thursday, September 10 at 2:00 p.m. PT from the Networked Society Stage (Booth 3673) in the Sands Expo.

In addition, the public may vote for their “Crowd Favorite.” Online voting begins now, and onsite text voting begins September 8. “Crowd Favorite” voting ends Thursday, September 10 at 10:00 a.m. PT.

About CTIA Super Mobility 2015

CTIA Super Mobility 2015 (ctiasupermobility2015.com) is the largest forum in the Western Hemisphere for the mobile innovations that power our connected life. More than 35,000 mobile professionals and executives and 1,100+ exhibitors from around the globe gather for this powerhouse technology event for its unrivaled networking opportunities and to share leading-edge trends, discoveries and knowledge. CTIA Super Mobility 2015 is held September 9, 10 & 11, 2015, at the Sands Expo and Convention Center in Las Vegas, USA.

Twitter: @ctiashows #SuperMobility | Facebook: ctiashows.com/facebook
LinkedIn: www.ctiashows.com/linkedin

About GTX Corp

GTX Corp (GTXO) is a pioneer in IoT and M2M wearable technology and a thought leader in enterprise 2 way GPS real-time personal location based services. Founded in 2002, headquartered in Los Angeles, California, with distributors in over 13 countries. The Company is known for its patented, innovative, game-changing and award-winning GPS SmartSole and its blockbuster Smartphone GPS Tracking App. GTX provides solutions that answer the “where” question: where is my mother, child, employee, vehicle, drone and high value assets.

Through a robust global enterprise monitoring IoT platform and licensing subscription business model, the Company offers a complete end to end solution of location based hardware, middleware, apps, global cell connectivity and professional services. Letting you know where or how someone or something is at the touch of a button, delivering security and peace of mind in an instant. GTX Corp also owns and operates LOCiMOBILE, Inc which develops applications for smart phones and tablets and Code Amber Alertag. The Company has a comprehensive intellectual property strategy and owns an extensive portfolio of patents, patents pending, registered trademarks, copy rights and URL’s and was recently featured in a 38 page research piece which outlines the value proposition of the Company’s IP portfolio.

Online: www.gtxcorp.com www.gpssmartsole.com

Consumer Purchase of GPS SmartSoles

Social media – #withyou
https://www.facebook.com/gtxcorpcom
http://www.twitter.com/gtxcorp
http://www.pinterest.com/GTXCorp/
http://instagram.com/gtxcorp

General information, licensing or investor relations:

213.489.3019
info@gtxcorp.com
http://www.gtxcorp.com/about/licenseinquiry
ir@gtxcorp.com

Disclaimer: GTX Corp does not warrant or represent that the unauthorized use of materials drawn from the content of this document will not infringe rights of third parties who are not owned or affiliated by GTX Corp. Further GTX Corp cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.

Forward Looking Statements

This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by GTX in light of its experience and its perception of current conditions and expected future developments, as well as other factors that GTX believes are appropriate in the circumstances. Many factors could cause GTX’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are set forth in GTX’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained at http://www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on GTX’s forward-looking statements. GTX has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: GTX Corp

ReleaseID: 431566

Upgrades Financial and Corporate Disclosures; Management Reiterates Debt Elimination Strategy

IRVINE, CA / ACCESSWIRE / August 27, 2015 / Cabinet Grow(R). (PINKSHEETS:CBNT), a developer and marketer of cabinet-based horticultural systems, announced the Company has secured eligibility by The Depository Trust Company (DTC) for its shares, effective August 26, 2015. Cabinet Grow also announced the Company has been approved to be up-listed to the OTCQB(R) Venture Marketplace and reiterated its strategy to be debt free in 90 days. The Company, based in Irvine, Calif., makes cabinet-based horticultural systems. The self-contained design and construction of the hydroponic and soil-based grow cabinets makes the process of home growing automated and simplified.

“We are pleased to announce that we have obtained DTC eligibility, while at the same time being up-listed to the OTCQB Marketplace,” said Sam May, chief executive officer of Cabinet Grow, Inc. “Cabinet Grow is committed to the high level of financial and corporate disclosure that is required for this listing category, and this is demonstrated in our rapid up-list to the OTCQB,” May said. “These accomplishments further validate our continued commitment to our shareholders and we believe that trading on the OTCQB and being DTC eligible will enhance trading liquidity and broaden our shareholder base as we continue to escalate market adoption of our horticulture products, solutions and related verticals.”

In addition, Cabinet Grow management has reiterated its strategy to eliminate corporate debt prior to year-end. The Company has finalized an agreement with its primary lender which limits debt conversions without the Company’s consent for 90 days following the agreement effective date and implements a maximum of $50,000 of debt conversions per month for three months beginning on day 91. There are no conversions in the 90 ninety days after effective date without Company approval.

“These milestones open the doors to institutional investors and market makers who were not previously able to buy and sell shares of our Company. Electronic trading is the standard in today’s financial markets, and becoming DTC-eligible greatly simplifies the process of trading and exchanging our common stock. Meeting the increased compliance and information requirements of OTCQB provides our investors greater confidence in the information disclosed by the Company and ensures our commitment to accountability and transparency. We will continue working towards our goals of up-listing in the future to a stock exchange such as the NASDAQ. Our ability to set higher goals and standards as a company is a direct result of sustained guidance from trusted contractors and advisors such as; VStock Transfer Agents, Legal and Compliance, Brooks and Associates, and Barry Hollander our CFO. As a public company, we rely heavily on these relationships and are optimistic we can build a strong company culture rich with the same integrity and courage demonstrated by our partners that will continue to serve our shareholders for years to come,” May added.

About Depository Trust Company

The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC, and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

About OTC Markets Group

In 2014, OTC Markets Group introduced standards and eligibility requirements for OTCQB with the goal of making it a better venture marketplace. To be eligible, companies must be current in their reporting to a U.S. or foreign regulator, pass a minimum bid price test of one penny ($0.01) and undergo an annual verification and management certification process providing additional information about the company’s insiders, advisors and share count. Companies that are approved to trade on OTCQB receive access to additional premium services to help them build visibility and improve transparency for investors.

About Cabinet Grow, Inc.

Cabinet Grow, Inc., through its predecessor Universal Hydro, began operations in California in 2008. In April 2014, the company changed its name to Cabinet Grow, Inc. and in May 2014 became a Nevada corporation. The Company, based in Irvine, Calif., makes cabinet-based horticultural systems. The self-contained design and construction of the hydroponic and soil-based grow cabinets makes the process of home growing automated and simplified. Our mission is to make hydroponic and soil growing simpler, more efficient and a better value than other products found on the market.

For more information, check out: http://www.cabinetgrow.com.

Forward-Looking Statements

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Form 10-K filed on March 31, 2015, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

Corporate Contact:
Cabinet Grow
17932 Sky Park Circle; Suite F
Irvine, CA 92614
888-54HYDRO (888-544-9376)
website: www.cabinetgrow.com
email: pressinquiry@cabinetgrow.com

Investor Contact:
Brett Maas
Hayden IR
brett@haydenir.com
646-536-7331

SOURCE: Cabinet Grow, Inc.

ReleaseID: 431584